IP Library Granted Patent US 10,131,878
Granted Patent B2
US 10,131,878 · App. 15/091,239 · Granted Nov 20, 2018

Methods for epicardial differentiation of human pluripotent stem cells

Inventors: Sean P. Palecek (Veron, WI); Xiaoping Bao (Madison, WI); Xiaojun Lian (Solna, SE)
Assignee: Wisconsin Alumni Research Foundation
C12N5/0657A61K35/34C12N2500/38C12N2500/95C12N2501/15C12N2501/415C12N2501/727C12N2501/998C12N2501/999C12N2506/02C12N2533/54
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,131,878
App. No.
15/091,239
Granted
Nov 20, 2018
Kind
B2
Abstract

Methods for generating high-yield, high-purity epicardial cells are described. Wnt/β-catenin signaling is first activated in human cardiac progenitor cells, by, for example, inhibiting Gsk-3 to induce differentiation into epicardial cells. Methods for long-term in vitro maintenance of human cardiac progenitor cell-derived epicardial cells and method comprising chemically defined, xeno-free, and albumin-free culture conditions are also provided.

Claims (19)

1. A method for generating a population of epicardial cells from human pluripotent stem cells, the method comprising culturing human cardiac progenitor cells, differentiated from human pluripotent stem cells, in a chemically defined, albumin-free culture medium that comprises an activator of Wnt/β-catenin signaling and that does not comprise Bone Morphogenetic Protein 4 (BMP4), whereby a cell population comprising human epicardial cells is obtained.

2. The method of claim 1 , wherein the human cardiac progenitor cells express one or more of Isl1, Nkx2.5, and Flk-1.

3. The method of claim 1 , wherein at least 95% of cells of the cell population are epicardial cells positive for expression of Wilms' tumor suppressor protein (WT1).

4. The method of claim 3 , wherein the epicardial cells are self-renewing for at least 25 population doublings when cultured in the presence of an inhibitor of TGFβ signaling.

5. The method of claim 1 , wherein the activator of Wnt/β-catenin signaling is a Gsk3 inhibitor.

6. The method of claim 5 , wherein the Gsk3 inhibitor is a small molecule selected from the group consisting of CHIR99021, CHIR98014, BIO-acetoxime, BIO, LiCl, SB216763, SB415286, AR A014418, 1-Azakenpaullone, and Bis-7-indolylmaleimide.

7. The method of claim 5 , wherein the Gsk3 inhibitor is CHIR99021 and is present in a concentration of about 0.2 μM to about 9 μM.

8. The method of claim 1 , wherein the human cardiac progenitor cells are obtained by a method comprising (i) culturing human pluripotent stem cells in a chemically defined, albumin-free culture medium comprising an activator of Wnt/β-catenin signaling to obtain a first cell population comprising mesodermal cells positive for expression of Brachyury/T; and (ii) culturing the first cell population in a chemically defined culture medium that comprises an inhibitor of Wnt/β-catenin signaling, whereby a cell population comprising human cardiac progenitor cells is obtained.

9. The method of claim 8 , wherein the human cardiac progenitor cells express one or more of Isl1, Nkx2.5, and Flk-1.

10. The method of claim 8 , wherein the activator of Wnt/β-catenin signaling is a Gsk3 inhibitor.

11. The method of claim 10 , wherein the Gsk3 inhibitor is a small molecule selected from the group consisting of CHIR99021, CHIR98014, BIO-acetoxime, BIO, LiCl, SB216763, SB415286, AR A014418, 1-Azakenpaullone, and Bis-7-indolylmaleimide.

12. The method of claim 8 , wherein the inhibitor of Wnt/β-catenin signaling is selected from the group consisting of a small molecule that stabilizes axin and stimulates β-catenin degradation, an inhibitor of porcupine, an antibody that blocks activation of a Wnt ligand receptor, an antibody that binds to one or more Wnt ligand family members, and a short hairpin interfering RNA (shRNA) for β-catenin in the first cell population.

13. The method of claim 12 , wherein the small molecule that stimulates β-catenin degradation and stabilizes axin is XAV939.

14. The method of claim 12 , wherein the porcupine inhibitor is selected from the group consisting of IWP2 and IWP4, or a combination thereof.

15. The method of claim 12 , wherein the porcupine inhibitor is present in a concentration of about 1 μM to about 4 μM.

16. The method of claim 1 , wherein no cell separation or selection step is used to obtain the cell population comprising epicardial cells.

17. A method for long-term in vitro maintenance of self-renewing human epicardial cells, the method comprising:

culturing human cardiac progenitor cells differentiated from human pluripotent stem cells in a chemically defined, albumin-free culture medium that comprises an activator of Wnt/β-catenin signaling and that does not comprise Bone Morphogenetic Protein 4 (BMP4), whereby a cell population comprising human epicardial cells is obtained; and

culturing the cell population comprising human epicardial cells in the presence of an inhibitor of TGFβ signaling, whereby the human epicardial cells are maintained in vitro as self-renewing epicardial cells for at least 25 population doublings, are not immortalized, and maintain the ability to undergo epithelial-to-mesenchymal transition (EMT).

Assignments (2)
CONFIRMATORY LICENSE Recorded May 16, 2018
From: WISCONSIN ALUMNI RESEARCH FOUNDATION
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 046172/0566 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 7, 2016
From: PALECEK, SEAN; BAO, XIAOPING; LIAN, XIAOJUN
To: WISCONSIN ALUMNI RESEARCH FOUNDATION
Reel/Frame 039101/0304 →
Continuity (2)
Provisional Application 62143359 · Apr 6, 2015
Related Publication 20170037375A1 · Feb 9, 2017